Wednesday, July 3, 2019

Eye Cancer Treatment Market Share and Growth Factors Impact Analysis 2018 – 2026

Eye cancer, also known as ocular cancer, occurs in the eye of children and adults. It is in the form of tumor which starts in and around the eye. There are two types of eye cancer. Primary intraocular cancer starts in the eyeballs. Primary intraocular melanoma is the most common type followed by primary intraocular lymphoma. Retinoblastoma is the most common form of primary intraocular cancer which mostly occurs in children. Secondary intraocular cancer is a metastatic cancer which starts from other parts of the body and spreads to the eyes. Secondary intraocular cancer is more common than primary intraocular cancer and is often metastatic form of breast and lung cancers. Risk of prevalence of an eye cancer is higher in Caucasians than in people from Asia or African Americans. People with certain inherited conditions such as dysplastic nevus syndrome, BAP1 cancer syndrome, and other conditions are more prone to suffer from eye cancer.


According to American Cancer Society estimates, there would be 3,360 new eye and orbit cancer cases, with 1, 860 in men and 1,500 in women, in 2019. Additionally, in the same year, 370 deaths are estimated to occur due to eye and orbit cancers, comprising 200 men and 170 women. According to NHS, 750 cases of ocular cancer in the U.K. are diagnosed every year.


Increase in incidence of eye cancers, surge in health care expenditure, and rise in risk factors such as geriatric population drive the global eye cancer treatment market. Moreover, rise in demand for innovative treatments including advanced surgeries and high investment by governments are anticipated to propel the global market during the forecast period. Technological advancements resulting in continuous innovation and rise in awareness about eye cancer symptoms and their common causes are expected to augment the global eye cancer treatment market from 2018 to 2026. Increase in secondary compared to primary eye cancers is likely to boost the growth of the global market in the next few years. Initiatives by governments to focus on the development of surgeries and investment in health care are the other factors projected to boost market growth. However, high cost of treatment, unavailability of skilled professionals especially in developing countries, and side effects of the treatment restrain the global eye cancer treatment market. Longer time taken by ocular cancer drugs to get approved by the regulatory bodies also hampers the growth of the market.
The global eye cancer treatment market can be segmented based on type, treatment, end-user, and region. In terms of type, the global market can be classified into eyelid tumor, corneal cancer, uveal melanoma, and orbital tumor. Corneal cancer is a squamous cell carcinoma of the conjunctiva which is a malignant tumor that occurs in the lining of the eyeballs and eyelids. An orbital tumor occurs in the orbit which is the bony socket containing an eye. Orbit tumor could be malignant or benign and can be either primary or metastatic. Rhabdomyosarcoma and retinoblastoma are the two most life threatening orbital tumors. Retinoblastoma is a malignant tumor that starts from the retina. It is most common in children and often passed on from the parents. Eyelid tumor occurs in sebaceous gland known as the carcinoma of the eyelid. Uveal melanoma is a primary malignant tumor which is the most common eye cancer. Based on treatment, the global eye cancer treatment market can be categorized into surgery, radiation therapy, laser therapy, chemotherapy, and others. The others segment includes thermotherapy and brachytherapy. In terms of end-user, the global market can be divided into hospitals, clinics, and ambulatory surgical centers.


In terms of region, the global eye cancer treatment market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Increase in demand for various surgical therapies for the treatment of eye cancers and rise in investment by governments in research & development of better eye cancer treatments boost the growth of the global eye cancer treatment market. North America dominated the global market in 2017 and the trend is projected to continue during the forecast period owing to the rising health care spending in the region and various innovative treatment offerings for eye cancer. Moreover, significant investments in research & development by companies and rise in awareness about eye cancers and their treatments are projected to boost the growth of the market in the U.S. Rise in the geriatric population is expected to increase the prevalence of primary eye cancers, as the risk increases with age. Europe is a prominent market for eye cancer treatments owing to the availability of treatment methods for eye cancer, high income of the population, and rise in demand for effective treatment. The eye cancer treatment market in Asia Pacific is anticipated to grow at a rapid pace during the forecast period. Rise in health care expenditure, rapidly expanding health care industry, and high unmet needs are likely to drive the market in the region during the forecast period. Technological advancements in the treatment of eye cancers and rise in disposal income are anticipated to propel the eye cancer treatment market in Asia Pacific during the forecast period. Additionally, the geriatric population is increasing in the highly populated counties in Asia Pacific which is a risk factor for eye cancers. This is projected to augment the global eye cancer treatment market during the forecast period. According to the American Academy of Ophthalmology, the incidence of uveal melanoma is lower in people from Asia and people of color.


Major players operating in the global eye cancer treatment market include Novartis AG, Spectrum Pharmaceuticals, Inc., GlaxoSmithKline plc, Bayer AG, Amgen, Inc., Takeda Pharmaceuticals Company Limited, Eli Lilly and Company, AstraZeneca, F. Hoffmann-La Roche Ltd., Janssen Global Services, LLC, Sanofi, AbbVie, Inc., Pfizer, Inc., Merck & Co., Inc., Bristol-Myers Squibb Company, and Oncomed Pharmaceuticals.

Spinal Intervention Market : Size, Application Analysis, Regional Outlook, 2018 -2026

Spinal intervention involves the treatment of all maladies that afflict the spine. The aim of spinal intervention is pain management, wherein the focus is solely on the spine. The spine consists of 33 bones, which include 12 thoracic vertebrae, seven cervical vertebrae, five sacral vertebrae, five lumbar vertebrae, and four coccygeal vertebrae. The pedicle, which is a stub of a bone that connects the lamina to the vertebral body to form an arch, is crucial in spinal intervention, as it offers a safe and secured tunnel. Through this tunnel, the interventionist examining the spine can get safe access to the vertebral body for vertebroplasty, biopsy, and kyphoplasty. The pedicles located in the cervical area are small and they have poor access to the vertebral body. The size of the pedicles gradually increases from the upper thoracic spine i.e. T4 to the lower lumbar spine i.e. L5. Progressive angulation occurs toward the cervical area from T4. Therefore, both pedicle size and angulation are equally important while planning a transpedicular procedure during intervention.


Spinal decompression is performed to create sufficient space for the nerves in the spinal canal, thereby diminishing the pain caused by neural impingement. Spinal fusion is performed to stop movement at one or more vertebral segments so as to relieve the pain and correct the spinal instability. The aim of spinal fusion is to unwind the spinal nerves that cause pain. This helps restore an appropriate gap between the vertebrae that surround the diseased disc, eliminating the pain caused during movement of the affected part.

Increase in the incidence of complications associated with the spine is one of the factors expected to increase health care costs worldwide. Other major factors are rise in the incidence of neurological diseases and neck deformities caused by obesity and injuries and increase in the incidence of degenerative disc disease, spondylolisthesis, prolapsed intervertebral circle, herniated disc, and spinal stenosis. The global spinal intervention market is expected to expand significantly in the next few years, due to high investments by major players in R&D activities and availability of government funds for promoting advanced technologies. However, lack of skilled, highly qualified, and well-experienced medical practitioners; high costs of surgery; and lack of awareness among patients about diagnosis are expected to be restraining factors for the global spinal intervention market during the forecast period.


The global spinal intervention market can be segmented based on surgery type, procedure type, technology, end-user, and region. Based on surgery type, the market can be segmented into open surgery and minimally invasive (MI) surgery. Due to occurrences of unsuccessful spinal surgeries, speedy research in newly developed techniques has been started to improve the outcome. Advancements in percutaneous techniques used in interventional procedures have lowered the invasive nature of the surgery. They have also avoided issues involved in open surgery such as infection and scarring. Based on procedure type, the global spinal intervention market can be classified into laminectomy, corpectomy, facetectomy, discectomy, and foraminectomy. Facetectomy is a procedure performed to remove the facet cartilage with the spine, which can promote easy fusion of bones. Non-fulfilment of this procedure can leave the facet articular cartilage inside, which may block the bone fusion by permitting the movement and contact between two cartilaginous surfaces in the particular part. Discectomy is a procedure allowing the removal of the herniated disc from the spinal canal. Laminectomy is a back surgery procedure performed to release the compressed spinal cord. Corpectomy is a procedure that helps relieve the damage caused to the vertebrae and the intervertebral discs. Foraminectomy is a spinal surgery procedure that decompresses the spinal nerves strained by the tissues, the disc material, or the bone that has narrowed the foraminal canal. Based on technology type, the global spinal intervention market can be classified into spinal fusion technology, spinal fixation technology, spinal non-fusion technology, annulus repair, dynamic stabilization, artificial disc replacement (or disc nucleus replacement), and vertebral compression fracture treatment. Based on end-user, the global spinal intervention market can be segregated into hospitals, research centers, and others.


Geographically, the global spinal intervention market can be divided into five major regions: North America, Asia Pacific, Europe, Latin America, and Middle East & Africa. The market in North America is expected to lead the global market during the forecast period, due to increasing number of spinal surgeries in countries in the region.


Prominent players operating in the global spinal intervention market are Abbott Laboratories Ltd., Medtronic Inc, Zimmer Biomet Holdings Inc, Orthofix International N.V., Stryker Corporation, Globus Medical Inc, Boston Scientific Corporation, BioControl Medical Ltd., Synapse Biomedical Inc., and DePuy Synthes Inc.

Sarcoidosis Therapeutics Market : Precise Analysis on Business Overview, Product Scope And Ongoing Market Development 2026

Sarcoidosis is a rare inflammatory disease characterized by the development of tiny lumps of cells in organs throughout the body. It is also known as Besnier-Boeck-Schaumann disease. The lumps are called granulomas. Granulomas can occur in the lymph nodes, skin, eyes, or other areas of the body; however, these mostly occur in the lungs. The cause of sarcoidosis is unclear. The disease can affect people of all ages, sex, and race. It is more common in African Americans and in people with Irish, German, Asian, Scandinavian, and Puerto Rican origin. Sarcoidosis appears most often in people aged between 20 and 40. It is not a contagious disease. It is estimated that only 30% of sarcoidosis patients develop chronic disease. In majority of cases, the disease can be cured within one or two years. Many people with sarcoidosis do not have any symptoms. Others have only vague symptoms such as night sweats, depression, sleep problems, loss of appetite, weight loss, and fever.


Sarcoidosis affects people of all ages across the world. Globally, women are more affected than men. The highest annual incidence has been observed in countries in Northern Europe at 5 to 40 cases per 100,000 people per year. African Americans are 3 times more likely to have sarcoidosis than Caucasian Americans.

The global sarcoidosis therapeutics market is expected to be driven by research undertaking and funding to control the rising prevalence of sarcoidosis. For instance, the National Institutes of Health (NIH) granted US$ 8.3 Mn to the University of Pittsburgh to explore the relationship between gene activation process, sarcoidosis disease progression, and lung bacteria. Other major trends in global sarcoidosis therapeutics include strategic alliances. Pharma companies are working together or with research organizations to develop medications for the treatment of sarcoidosis. In March 2015, THERAMetrics Holding AG signed collaboration and licensing agreement with Centurion Pharma to develop and commercialize Aviptadil for sarcoidosis. In December 2018, aTyr Pharma announced collaboration with Foundation for Sarcoidosis Research (FSR) for assistance in clinical trial site initiation and patient enrollment for pulmonary sarcoidosis. Institutions and organizations are spreading awareness about sarcoidosis among people. In the U.K., the British Lung Foundation (BLF) is creating awareness about the early diagnosis and therapeutics of sarcoidosis.


The global sarcoidosis therapeutics market can be segmented based on therapy and route of administration. In terms of therapy, the global sarcoidosis therapeutics market can be categorized into immunosuppressant drugs, tumor necrosis factor alpha (TNF-α) blockers, corticosteroids, and others. Prednisone is the most common corticosteroid prescribed for sarcoidosis. Immunosuppressant drugs such as methotrexate could be given to people who are unable to take corticosteroids. Based on route of administration, the global sarcoidosis therapeutics market can be classified into intravenous, oral, subcutaneous, and inhalation. Inhaled corticosteroids are used to treat lung-related symptoms of sarcoidosis.

In terms of region, the global sarcoidosis therapeutics market can be segmented into North America, Asia Pacific, Europe, Latin America, and Middle East & Africa. North America is projected to lead the global sarcoidosis therapeutics market during the forecast period. The region’s dominance is attributed to industry and academia partnership and funding to encourage more research on sarcoidosis and research undertaken by various pharma companies. Asia Pacific is anticipated to be the fastest growing sarcoidosis therapeutics market owing to grants received from various international associations and rise in prevalence rate.



Key players operating in the global sarcoidosis therapeutics market are Merck & Co., Inc., Bellus Health, Novartis AG, Araim Pharmaceuticals, Inc., FirstString Research, Inc., Relief Therapeutics, Adaptimmune Therapeutics plc, PharmaIN Corporation, EpiZyme, Inc., and Advenchen Laboratories, LLC.

Pneumonia Testing Market : Research and Analyzed Report for 2018 – 2026

Pneumonia is a type of lung infection caused by microorganisms such as bacteria, viruses, fungi, and parasites. Streptococcus pneumonia is one of the most common causes of pneumonia among children. Others are Haemophilus influenzae type b (Hob) and Pneumocystis jiroveci. It is characterized by symptoms such as shortness of breath, fever, chest pain, nausea, and vomiting. In pneumonia, the air sacs of the lungs called alveoli are filled with fluid or pus that causes inflammation. The treatment of pneumonia depends on the severity of symptoms and types of pathogens. Usually, antibiotics are given to treat pneumonia caused by bacterial infections. In order to treat pneumonia caused by fungi, antifungals are prescribed. It is quite difficult to diagnose pneumonia as its clinical symptoms overlap with many other diseases such as asthma, bronchitis, and common cold.


The global pneumonia testing market is expected to expand significantly due to an increase in the aging population, recent advances in pneumonia diagnostics, and high prevalence of pneumonia among children. Rapid increase in the aging population in North America, Europe, and Japan is expected to drive the market in these regions as elderly people are more susceptible to developing pneumonia compared to the general population. UNICEF suggests that pneumonia is one of the major factors causing death in children. In 2016, approximately 880,000 children under the age of five years died due to pneumonia. Most of its victims were less than two years old. This disease is most prevalent in South Asia and African countries. Recent advancement in pneumonia diagnostics such as the development of nucleic acid detection tests for major pneumonia pathogens and immunochromatographic pneumococcal urinary antigen tests are anticipated to drive the market.
The global pneumonia testing market can be segmented based on product, technology, method, end-user, and geography. Based on product, the market can be divided into analyzers and consumables. In terms of technology, the market can be segmented into enzyme-linked immunosorbent assay (ELISA), immunofluorescence, western blot, polymerase chain reaction (PCR), immunohistochemistry (IHC), and others. Based on method, the market can be segmented into immunodiagnostics, molecular diagnostics, and point of care (POC) testing. In terms of end-user, the market can be divided into hospitals, diagnostics laboratories, homecare, and others.


Based on region, the pneumonia testing market can be categorized into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. Each of these regions can be sub-segmented into specific countries such as the U.S. and Canada (North America), the U.K. and Germany (Europe), Brazil (Latin America), China and India (Asia Pacific), and GCC countries (Middle East & Africa). North America dominated the global pneumonia testing market, due to a rise in the geriatric population and increase in demand for innovative medical technology in the region. Asia Pacific is expected to be a highly attractive region of the pneumonia testing market during the forecast period, due to an increase in health care awareness and high demand for advanced medical technology in the region.



Key players operating in the pneumonia testing market are Thermo Fisher Scientific Inc., Abbott Laboratories, F-Hoffmann la Roche Ltd., Hologic Inc., bioMerieux, Becton, Dickenson and Company, Bio-Rad Laboratories Inc., DiaSorin, Quest Diagnostics, and Meridian Biosciences. Some diagnostic kits available in the market are Directigen S. pneumonia test kit by Becton Dickinson and LCx Chlamydia pneumonia PCR assay kit by Abbott Laboratories. In order to gain a competitive advantage in the industry, these players are adopting various growth strategies, such as collaborations, agreements, partnerships, and new product launches.

Optogenetics Actuators and Sensors Market Report Explored in Latest Research 2018 – 2026

Global Optogenetics Actuators and Sensors Market: Overview

Optogenetics actuators and sensors is a new innovation that combines optics and genetics. It allows one to measure or manipulate the characteristic of identified neurons or cells in a tissue with the aid of light with an accuracy with in the time span of milliseconds, also in an animal who is moving freely. Optogenetics actuators and sensors is an effective tool for revealing the underlying behavior of neural mechanisms and reading different types of physiological phenomena.

The report gives a clean image of modern marketplace scenario that includes beyond and expected future market size with its value and volume, technological advancement, governing and macro-economic factors in the market. The report provides detail facts and techniques utilized by top key players in the sector. The study also provides a broad study of the exclusive market segments and regions. 



Global Optogenetics Actuators and Sensors Market: Drivers and Restraints

Elements responsible for an increment of the global optogenetics actuators and sensors market are rising due to a surge in neurological disorders and retinal disease, fast growth, and study in the field of optogenetics, and government initiatives like subsidizing help for advancement of this field. Optogenetics actuators and sensors grant information that biochemical and physiological pathway is operating for the reason of specific disease. This disease may find treatment for specific disease by methods of blazing blue light on particular neural cells.

Optogenetics actuators and sensors permit enactment or restraint of the particular neurons with a high degree of neurochemical, spatial, and temporal accuracy that boost the global marketplace. This methodology can be used to control development of neuron and to perceive the working of brain cells which is at a cellular level that still raises the global optogenetics actuators and sensors market.
However, increasing cost of innovation is projected to affect market development. Alongside ethical regulation for animal welfare, this is likewise foreseen to subside the development of the global optogenetics actuators and sensors market. In any case, an improved study in the field of ophthalmology and neuroscience is projected to boost the market. In addition, various steps are taken by global organizations like NIH and WHO are foreseen to boost the global optogenetics actuators and sensors market development.


Global Optogenetics Actuators and Sensors Market: Geographical Outlook
Based on geography, North America is expected to be the dominant region in the global optogenetics actuators and sensors market. There is strong government funding to carry research and development in this field as optogenetics has potential to understand better pathophysiology in chronic neural disease. Asia Pacific is expected to show the quickest development over the forecast period due to favorable government support and progressive industrialization.

Global Optogenetics Actuators and Sensors Market: Competitive Landscape
Global optogenetics actuators and sensors market is highly fragmented and the major players have used various strategies to increase their footprints in the global optogenetics actuators and sensors market. Key players are concentrating on research activities to study brain, which are expected to drive the sector. Some of the major market players are Gensight Biologics, Elliot Scientific Ltd., and Thorlabs, Inc., among others.



The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

Oral Cancer Treatment Market Current Trends and Future Aspect Analysis 2026

Oral or mouth cancer usually occur on the surfaces of tongue, lips, cheek, gums, tonsils and salivary glands. An oral cancer is a type of head and neck cancer; and it appears in the form of a tumor in the mouth. Oral cancers can be benign or malignant. Benign tumors can be removed with the help of surgery. 90% of malignant oral cancers comprise of squamous cell carcinoma, which could spread to other parts of the body. According to the Oral Cancer Foundation, every year around 53,000 new oral cancer cases are diagnosed and more than 9,750 people succumb to the disease in the U.S. Oral cancer accounts for 4% of total cancer cases and causes 2.2% of deaths in the U.S. In western countries, prevalence of oral cancer is 2% to 6% of the total cancer cases. In Asia Pacific, the oropharyngeal cancer is more common among men than women. According to the National Cancer Institute, 60% of people with oral cancer survive for five years or more and 70% to 90% of people with Stage 1 or 2 cancer survive for more than 5 years.


Increase in incidence of oral cancers, surge in health care expenditure, and rise in risk factors such as growing age, increase in HPV16 are some factors driving the global oral cancer treatment market. Additionally, increasing usage of tobacco worldwide is a major factor driving the oral cancer treatment market. According to a report by the World Health Organization (WHO), the worldwide tobacco use is 4 Million which is growing annually and death caused due to tobacco is likely to reach 10 million by 2020. Rising alcohol consumption across the globe is also another major factor causing oral cancer. This, in turn, is likely to propel the global oral cancer treatment market. Moreover, rise in patient population and high investments by governments for providing better oral cancer treatment are anticipated to propel the market during the forecast period. However, ignoring early symptoms of oral cancer and lack of awareness about the disease, especially in developing countries is likely to restrain the global market.

Global oral cancer treatment market can be segmented based on type, treatment, end-users, and region. Based on type of oral cancer, the market can be classified into verrucous carcinoma, squamous cell carcinoma, minor salivary gland cancers, and others. Based on treatment, the global oral cancer treatment market can be categorized into surgery, radiation therapy, targeted therapy, chemotherapy, and others. In terms of end-users, the global market can be divided into hospitals, specialized cancer centers, and others.


In terms of region, the global oral cancer treatment market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Increase in demand for surgical therapies for the treatment of oral cancer and rise in investment by governments in research & development to improve treatments boost the global market. North America dominated the global market in 2017 and this trend is projected to continue during the forecast period owing to the rising health care investments in the region and prevalence of oral cancer. Europe is a major region for the oral cancer treatment market owing to the availability of funds for oral cancer, huge patient population, and high income of people in the region. The oral cancer treatment market in Asia Pacific is anticipated to expand at a rapid pace during the forecast period. Rise in tobacco usage, increase in smoking, rapidly expanding health care industry, growing patient population, and high unmet needs are likely to drive the oral cancer treatment market in the region. Further, favorable government policies and rise in disposal income are anticipated to propel the oral cancer treatment market in the region during the forecast period.



Major players operating in the global oral cancer treatment market include Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Eli Lilly and Company, Novartis AG, Pfizer Inc., and Teva Pharmaceutical Industries Ltd.

Acute Repetitive Seizures Market : Global Market Revenue and Share by Manufacturers

The acute repetitive seizure is a condition that occurs in patients with drug-refractory epilepsy. It is also known as cluster seizure, seizure flurry, breakthrough seizure, seizure cluster, serial seizure, or prolonged seizure. The acute repetitive seizure is characterized by the occurrence of seizures within short intervals, which could be within hours or even a few minutes. The frequency of occurrence of these seizures depends upon the type of epilepsy such as mesial temporal lobe epilepsy and the patient characteristics. Three catamenial seizures occur within two premenstrual days in women with mesial temporal lobe epilepsy. Rectal gels and nasal sprays are used for the management of acute repetitive seizures.


Increase in the number of clinical trials, a rise in emphasis on the launch of new therapies, and the surge in demand for nasal sprays for the treatment of epilepsy are the major factors projected to drive the global acute repetitive seizures market. Additionally, an increase in the number of regulatory approvals and promising drugs in the pipeline is anticipated to fuel the growth of the acute repetitive seizures market during the forecast period. For instance, in April 2018, UCB S.A. announced that the Food and Drug Administration (FDA) accepted a new drug application (NDA) for Nayzilam (midazolam) nasal spray indicated for the treatment of seizures such as seizure clusters and acute repetitive seizures. This could result in the approval of the drug in early 2019, making it the first ever medication approved by the FDA in more than 17 years.


The global acute repetitive seizures market can be segmented based on product, route of administration, distribution channel, and region. In terms of product, the acute repetitive seizures market can be divided into USL-261, VALTOCO, AZ-002, Diastat rectal gel, and others. Based on the route of administration, the global acute repetitive seizures market can be classified into nasal, oral, rectal, and others. The nasal segment is anticipated to expand at the fastest CAGR during the forecast period due to shifting from rectal to nasal route of administration and increase in the number of patients preferring nasal sprays due to ease of administration. In terms of the distribution channel, the acute repetitive seizures market can be categorized into hospital pharmacies, retail pharmacies, and online pharmacies. The retail pharmacies segment is expected to expand at the fastest CAGR owing to increase in the availability of medications for serious disease conditions at these pharmacies, ease of access, an increase in the chain of retail pharmacies supplying medications for acute repetitive seizures.

The global acute repetitive seizures market can be segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is projected to account for the largest market share during the forecast period. The acute repetitive seizures market in the region is driven by an increase in the number of pharmaceutical companies engaged in new drug development and rise in prevalence of epileptic seizures. In September 2018, Neurelis, Inc., a pharmaceutical company based in San Diego, the U.S., submitted a New Drug Application (NDA) with the FDA for VALTOCO as a treatment for epilepsy patients with acute repetitive seizures. The acute repetitive seizures market in Europe is anticipated to grow at a rapid pace from 2018 to 2026 due to rise in investment in research and development in the field of neurology, increase in funds offered by the government, and surge in demand for medications for epilepsy. The market in the Asia Pacific is expected to expand at the fastest CAGR during the forecast period driven by rising in awareness about the treatment of neurological disorders and increase in demand for new drug formulations for treating serious conditions in neurology.



Key players operating in the global acute repetitive seizures market are UCB S.A., Neurelis, Inc., Alexza Pharmaceuticals, and Valeant Pharmaceuticals North America LLC.